Category: News & Events

Five-Year Clinical Outcomes After XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) Implantation

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at evaluating 5-year effectiveness and safety in participants after XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) implantation.

From December 2013 to May 2014, 108 patients (127 lesions) were treated with the XIENCE PRIME EECSS. The entire follow-up included annual assessments for 5 years after treatment or until one of the clinical endpoints was reached. We evaluated the 5-year clinical outcomes with Kaplan-Meier analysis and the Cox regression model.

Nearly three-quarters of the participants were men (76.8%), and the average age was 65.6 ± 10.8 years. Bifurcation lesions accounted for 96.1% (122 lesions), and left main lesions accounted for 3.9% (five lesions), with a total count of 127 lesions. The cumulative rate of major adverse cardiac events was as follows: 1 year, 1.9%; 2 year, 4.0%; and 5 year, 10.0%. No definite or probable stent thrombosis was observed, and the rate of target lesion failure was only 3.3% over 5 years. The cumulative rate of major bleeding eventually increased to only 4.4%.

The 5-year clinical outcomes were favorable in patients treated with XIENCE PRIME EECSS, and the incidence of stent thrombosis and target lesion failure was relatively low. The incidence of major bleeding gradually increased but remained moderate.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0013

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Rongrong Shen, Peiyu Zhang and Jing Liu et al. Five-Year Clinical Outcomes After XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) Implantation. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0013

Loading

Advances in the Application of Pulsed Field Ablation for Arrhythmia Treatment

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The increased application of catheter ablation to treat cardiac arrhythmias has contributed to continued exploration of safe and effective tissue ablation tools in the field of electrophysiology. Pulsed field ablation (PFA), a novel recently developed non-thermal energy-based technique, uses trains of microsecond duration high-amplitude pulses to ablate target cells. Several preclinical and clinical studies have demonstrated that PFA is a promising tool for cardiac ablation to treat arrhythmia. In addition to being an effective tissue ablation technique, PFA is safe, because it avoids damage to the surrounding cells/tissues. This article focuses on efficacy and safety outcomes reported in preclinical and clinical studies evaluating the effects of PFA on arrhythmia, and discusses limitations and potential future directions of PFA.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0019

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Fuding Guo, Jun Wang and Liping Zhou et al. Advances in the Application of Pulsed Field Ablation for Arrhythmia Treatment. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0019

Loading

Experience in Application of a Three-Dimensional Pulsed Field Ablation System Integrating Mapping and Ablation

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Pulsed field ablation (PFA), a promising technology for ablating arrhythmias, has significantly better efficiency and potentially greater safety than traditional ablation techniques using thermal injury. However, most clinical research on PFA for ablation to date has used basket- or flower-shaped catheters, thus requiring a large introducing sheath and catheter location under fluoroscopic guidance. The authors of this article describe initial experiences with using a three-dimensional PFA system integrating mapping and ablation, and an annular catheter.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0009

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yan Wang, Jie Qiu and Daowen Wang. Experience in Application of a Three-Dimensional Pulsed Field Ablation System Integrating Mapping and Ablation. CVIA. 2023. Vol. 7(1). DOI: 10.15212/CVIA.2023.0009

Loading

Advances in Renal Denervation in the Treatment of Hypertension

Hypertension significantly increases the risk of cardiovascular events and it is associated with high rates of disability and mortality. Hypertension is a common cause of cardiovascular and cerebrovascular accidents, which severely affect patients’ quality of life and lifespan. Current treatment strategies for hypertension are based primarily on medication and lifestyle interventions. The renal sympathetic nervous system plays an important role in the pathogenesis of hypertension, and catheter-based renal denervation (RDN) has provided a new concept for the treatment of hypertension. In recent years, studies on RDN have been performed worldwide. This article reviews the latest preclinical research and clinical evidence for RDN.

Announcing a new article publication for Cardiovascular Innovations and Applications journal.   

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0014

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Bin Xiong, Shaojie Chen and Weijie Chen et al. Advances in Renal Denervation in the Treatment of Hypertension. CVIA. 2023. Vol. 7(1). DOI: 10.15212/CVIA.2023.0014

Loading

Machine Learning Methods in Real-World Studies of Cardiovascular Disease

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Cardiovascular disease (CVD) is one of the leading causes of death worldwide, and answers are urgently needed regarding many aspects, particularly risk identification and prognosis prediction. Real-world studies with large numbers of observations provide an important basis for CVD research but are constrained by high dimensionality, and missing or unstructured data. Machine learning (ML) methods, including a variety of supervised and unsupervised algorithms, are useful for data governance, and are effective for high dimensional data analysis and imputation in real-world studies. This article reviews the theory, strengths and limitations, and applications of several commonly used ML methods in the CVD field, to provide a reference for further application.

This article introduces the origin, purpose, theory, advantages and limitations, and applications of multiple commonly used ML algorithms, including hierarchical and k-means clustering, principal component analysis, random forest, support vector machine, and neural networks. An example uses a random forest on the Systolic Blood Pressure Intervention Trial (SPRINT) data to demonstrate the process and main results of ML application in CVD.

ML methods are effective tools for producing real-world evidence to support clinical decisions and meet clinical needs. This review explains the principles of multiple ML methods in plain language, to provide a reference for further application. Future research is warranted to develop accurate ensemble learning methods for wide application in the medical field.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0011

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jiawei Zhou, Dongfang You and Jianling Bai et al. Machine Learning Methods in Real-World Studies of Cardiovascular Disease. CVIA. 2023. Vol. 7(1). DOI: 10.15212/CVIA.2023.0011

Loading

Elevated Monocyte to High-density Lipoprotein Ratio Is a Risk Factor for New-onset Atrial Fibrillation after Off-pump Coronary Revascularization

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Atrial fibrillation (AF) is a common complication of coronary revascularization. Currently, the mechanisms of postoperative AF are unclear. This study was aimed at investigating the risk factors for new-onset AF (NOAF) after coronary revascularization and exploring the early warning effects of clinical inflammatory markers. A retrospective analysis was conducted on 293 patients with unstable angina pectoris who underwent coronary artery revascularization in Beijing Chao-Yang Hospital, Capital Medical University, between April 2018 and June 2021, including 224 patients who underwent coronary artery bypass grafting and 69 patients who underwent one-step hybrid coronary revascularization. Baseline data, clinical data, blood indicators and AF episodes within 7 days after the surgery were collected. Participants were divided into two groups according to whether AF occurred, and the data were analyzed between groups. In addition, multivariate logistic regression was used to explore the independent risk factors for developing AF post coronary revascularization.

Aging, a larger left atrial inferior-superior diameter, use of an intra-aortic balloon pump, a greater blood volume transfused during perioperative period and a higher monocyte to high-density lipoprotein ratios on postoperative day 1 were independent risk factors for NOAF after coronary artery surgery.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0012

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yameng Mu, Jiayin Niu and Min Zhang et al. Elevated Monocyte to High-density Lipoprotein Ratio Is a Risk Factor for New-onset Atrial Fibrillation after Off-pump Coronary Revascularization. CVIA. 2023. Vol. 7(1). DOI: 10.15212/CVIA.2023.0012

Loading

Optimal Blood Pressure Control Target for Older Patients with Hypertension: A Systematic Review and Meta-Analysis

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study evaluated the optimal systolic blood pressure (SBP) target for older patients with hypertension.

A Bayesian network meta-analysis was conducted. The risk of bias of the included studies was assessed by using a modified version of the Cochrane risk of bias. The trial outcomes comprised the following clinical events: major adverse cardiovascular events (MACE), cardiovascular mortality, all-cause mortality, myocardial infarction, heart failure and stroke.

A total of six trials were included. All treatment therapies were reclassified into three conditions according to the final achieved SBP after intervention (<130 mmHg, 130–139 mmHg and ≥140 mmHg). The results demonstrated that anti-hypertensive treatment with an SBP target <130 mmHg, compared with treatment with an SBP target ≥140 mmHg, significantly decreased the incidence of MACE (OR 0.43, 95%CI 0.19–0.76), but no statistical difference was found in other comparisons. Although the results showed a trend toward more intensive anti-hypertension therapy having better effects on preventing cardiovascular mortality, all-cause mortality, myocardial infarction, heart failure, and stroke, no significant differences were found among groups.

The meta-analysis suggested that SBP <130 mmHg might be the optimal BP control target for patients ≥60 years of age; however, further evidence is required to support these findings.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0008

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Article reference: Yuling Yan, Yue Han and Bin Liu et al. Optimal Blood Pressure Control Target for Older Patients with Hypertension: A Systematic Review and Meta-Analysis. CVIA. 2023. Vol. 7(1). DOI: 10.15212/CVIA.2023.0008

Loading

Immune Infiltration in Atherosclerosis is Mediated by Cuproptosis-Associated Ferroptosis Genes

Announcing a new article publication for Cardiovascular Innovations and Applications journal. In this study, the authors identify cuproptosis-associated ferroptosis genes in the atherosclerosis microarray of the Gene Expression Omnibus (GEO) database and explored hub gene-mediated immune infiltration in atherosclerosis.

Immune infiltration plays a crucial role in atherosclerosis development. Ferroptosis is a mode of cell death caused by the iron-dependent accumulation of lipid peroxides. Cuproptosis is a recently discovered type of programmed cell death. No previous studies have examined the mechanism of cuproptosis-associated ferroptosis gene regulation in immune infiltration in atherosclerosis.

The qualified atherosclerosis gene microarray was researched in the GEO database, integrated with ferroptosis and cuproptosis genes, and calculated with the correlation coefficients. The authors then obtained the cuproptosis-associated ferroptosis gene matrix and screened differentially expressed genes. Subsequently, they performed Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses and protein–protein interaction network analysis of differentially expressed genes. The authors also screened hub genes according to the Matthews correlation coefficient (MCC) algorithm. The authors conducted enrichment analysis of hub genes to explore their functions and predict related microRNAs (P<0.05). The authors also used the single-sample gene set enrichment analysis (ssGSEA) algorithm to analyze the relationships between hub genes and immune infiltration, and used immune-associated hub genes to construct a risk model. Finally, the authors used the drug prediction results and molecular docking technology to explore potential therapeutic drugs targeting the hub genes.

Seventy-eight cuproptosis-associated ferroptosis genes were found to be involved in the cellular response to oxidative and chemical stress, and to be enriched in multiple pathways, including ferroptosis, glutathione metabolism, and atherosclerosis. Ten hub genes were identified with the MCC algorithm; according to the ssGSEA algorithm, these genes were closely associated with immune infiltration, thus indicating that cuproptosis-associated ferroptosis genes may participate in atherosclerosis by mediating immune infiltration. The receiver operating characteristic curve indicated that the model had a good ability to predict atherosclerosis risk. The results of drug prediction (adjusted P<0.001) and molecular docking showed that glutathione may be a potential therapeutic drug that targets the hub genes.

The conclusion was that cuproptosis-associated ferroptosis genes are associated with immune infiltration in atherosclerosis.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0003

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Article reference: Boyu Zhang, Shuhan Li and Hanbing Liu et al. Immune Infiltration in Atherosclerosis is Mediated by Cuproptosis-Associated Ferroptosis Genes. CVIA. 2023. Vol. 7(1). DOI: 10.15212/CVIA.2023.0003

Loading

Association between Percentage of Neutrophils at Admission and in-Hospital Events in Patients 75 Years of Age or more with Acute Coronary Syndrome

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  This study evaluated the role of the neutrophil percentage (N%) at admission in predicting in-hospital major adverse cardiovascular events (MACE) in patients ≥75 years of age with acute coronary syndrome (ACS).

A total of 1189 patients above 75 years of age with ACS hospitalized at the Second Xiangya Hospital between January 2013 and December 2017 were enrolled in this retrospective study. Receiver operator characteristic curve analysis was performed to calculate the optimal N% cut-off value for patient grouping. The in-hospital MACE consisted of acute left heart failure, stroke and any cause of death. Multivariable logistic analyses were used to assess the role of N% in predicting MACE in older patients with ACS.

The patients were divided into a high N% group (N% ≥74.17%, n=396) and low N% group (N%<74.17%, n=793) according to the N% cut-off value (N%=74.17%). The rate of MACEs during hospitalization was considerably higher in the high N% group than the low N% group (27.5% vs. 9.6%, P<0.001). After adjustment for other factors, high N% remained an independent risk factor for in-hospital MACE in older patients with ACS (odds ratio 1.779, 95% confidence interval 1.091–2.901, P=0.021).

High N% at admission is an independent risk factor for in-hospital MACE in patients above 75 years of age with ACS.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0010

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Article reference: Cuihong Tian, Zhaowei Zhu and Hebin Xie et al. Association between Percentage of Neutrophils at Admission and in-Hospital Events in Patients ≥75 Years of Age with Acute Coronary Syndrome. CVIA. 2023. Vol. 7(1). DOI: 10.15212/CVIA.2023.0010

Loading

Call for Papers

You are invited to submit an article to Cardiovascular Innovations and Applications (CVIA).

Cardiovascular Innovations and Applications (CVIA) seeks to publish focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification.

CVIA was launched in 2015 as an open access journal, offering high visibility and discoverability through its open access publishing approach. As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, CVIA will actively support authors through open access publishing and through waiving author fees.  

The journal welcomes the following article types:

  • Editorials
  • Original Research
  • Review Articles
  • Commentaries
  • Case Reports
  • Case Studies
  • Methodology papers related to clinical trials
  • Letters to the Editor

For more information on our journal please see the CVIA website https://cvia-journal.org/; recently published content is available on ScienceOpen  https://www.scienceopen.com/search#collection/32b77252-732d-468f-a6f9-9637d4762967 .

Submissions to Cardiovascular Innovations and Applications (CVIA) can be made using ScholarOne, the online submission and peer review system. Registration and access is available at https://mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

CVIA is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases.

Follow CVIA on Twitter @CVIA_Journal; or Facebook https://www.facebook.com/cvia.journal/.

Articles of interest include:

Psychosocial Risk Factors and Cardiovascular Disease: Epidemiology, Screening, and Treatment Considerations

Novel SPECT Technologies and Approaches in Cardiac Imaging

Global Burden of Cardiovascular Disease

Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study

Rationale and Design of the Randomized Controlled Trial of Intensive Versus Usual ECG Screening for Atrial Fibrillation in Elderly Chinese by an Automated ECG System in Community Health Centers in Shanghai (AF-CATCH)

The Effect of Home-Based Cardiac Rehabilitation on Functional Capacity, Behavior, and Risk Factors in Patients with Acute Coronary Syndrome in China

Current Management Strategies in Patients with Heart Failure and Atrial Fibrillation: A Review of the Literature

Telemedicine: Its Importance in Cardiology Practice. Experience in Chile

Management of Hypertension: JNC 8 and Beyond

The Relationship Between Mean Platelet Volume and In-Hospital Mortality in Geriatric Patients with ST Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention

Loading